Purpose Individualizing gastric-resistant tablets is associated with major challenges for clinical staff in hospitals and healthcare centres. This work aims to fabricate gastricresistant 3D printed tablets using dual FDM 3D printing. Methods The gastric-resistant tablets were engineered by employing a range of shell-core designs using polyvinylpyrrolidone (PVP) and methacrylic acid co-polymer for core and shell structures respectively. Filaments for both core and shell were compounded using a twin-screw hot-melt extruder (HME). CAD software was utilized to design a capsuleshaped core with a complementary shell of increasing thicknesses (0.17, 0.35, 0.52, 0.70 or 0.87 mm). The physical form of the drug and its integrity following an FDM 3D printing were assessed using x-ray powder diffractometry (XRPD), thermal analysis and HPLC. Results A shell thickness ≥0.52 mm was deemed necessary in order to achieve sufficient core protection in the acid medium. The technology proved viable for incorporating different drug candidates; theophylline, budesonide and diclofenac sodium. XRPD indicated the presence of theophylline crystals whilst budesonide and diclofenac sodium remained amorphous in the PVP matrix of the filaments and 3D printed tablets. Fabricated tablets demonstrated gastric resistant properties and a pH responsive drug release pattern in both phosphate and bicarbonate buffers. Conclusions Despite its relatively limited resolution, FDM 3D printing proved to be a suitable platform for a singleprocess fabrication of delayed release tablets. This work reveals the potential of dual FDM 3D printing as a unique platform for personalising delayed release tablets to suit an individual patient's needs.
INTRODUCTION
Latest advances in pharmacogenomics and clinical trials have put more emphasis on individualizing treatment in a patientcentred health care (1) . One important aspect of personalizing treatment is individualizing dosage forms. In case of solid dosage forms, dose personalization by splitting of tablets has been associated with dose variation (2, 3) . Moreover, the splitting of coated tablets physically compromises the barrier function of the coating, rendering dose adjustment impractical for delayed and modified release tablets (4) . One potential solution for personalising the dose of solid dosage forms is the ondemand manufacturing by using a benchtop 3D printer (5) . This approach offers several advantages to both healthcare workers and patients, such as flexibility in modifying the dose, shape and size of the dosage form in response to an individual patient's or healthcare staff's needs (6) . Therefore, it would be of great interest to fabricate an enteric dosage using a benchtop 3D printer.
Enteric coated formulations are produced by carrying out two main steps; i) production of an API-loaded core, and ii) coating the core with synthesized or semi-synthetized polymers (7, 8) . The technology requires paradoxical criteria of no or limited drug release in acid medium followed by the release of 80% of the actives in the intestinal phase within a certain time limit (9) . These criteria are usually met by applying a 30-100 μm thick film to a core (e.g. tablets, pellets). However, achieving such a demanding criteria via 3D printing technologies creates some major technical challenges such as i) grafting a consistent protective shell within the resolution of 3D printers, ii) achieving adhesion and compatibility between the shell and core materials, and iii) coordinating simultaneous applications of the shell and core materials.
These challenges were reflected by the absence of literature reports utilizing 3D printing technologies for the fabrication of delayed release shell-core tablets. Although powder based 3D printing have been reported for immediate and controlled release (10) (11) (12) , no examples of delayed release tablets meeting the pharmacopeial criteria have been reported. Yet, one relevant attempt was the use of TheriForm technology (powder-based 3D printing) to manufacture a dual pulsatile release system composed of 3 chambers (11, 13) . In the enteric chamber, an ethanolic solution of the enteric polymer was sprayed onto a mixture of lactose and MMC, resulting in a pH dependent behaviour and a drug release over 4 h in the intestinal phase.
With increased interest in FDM 3D printing in fabrication of oral tablets for extended (5, (14) (15) (16) and immediate drug release (17) (18) (19) , few attempts have been reported utilising the technology for enteric tablets. For instance, FDM 3D printed PVA based tablets were coated with methacrylic polymer to target the colon using a conventional fluidized bed coater (20) . More recently, a double disc containing an enteric layer was fabricated by FDM 3D printing and the drug release from the disc was assessed using a test cell assembly (21) . As far as the authors know, there have been no previous examples of complete production of delayed release tablets through 3D printing.
Recent technological advances have made 3D printers available with multiple nozzles. Such advances paved its way in artistic designs (22, 23) , the manufacturing of composite elements (24) , as well as pharmaceutical applications (25) . In this effort, we aim to fabricate an enteric coated tablet using a dual-nozzle single step FDM 3D printing process. The gastric-resistant tablets were engineered by employing a range of shell-core designs using polyvinylpyrrolidone (PVP) and methacrylic acid copolymer for core and shell structures respectively, such polymers have been also broadly exploited in supporting other advance techniques (26, 27) . Theophylline was used initially as a model drug for its thermal stability, small molecular weight and high water solubility, rendering it an ideal model drug to test the efficiency of controlling drug release from the enteric system. Later, other model drugs commonly available as gastric-resistant products (budesonide and sodium diclofenac) were deployed in this system.
MATERIALS AND METHODS

Materials
Theophylline was purchased from Acros Organics (UK). Polyvinylpyrrolidone (PVP, MW 40,000), PEG400, castor oil, triethyl citrate, tribasic phosphate (TBP), oleic acid and dipyridamole were purchased from Sigma-Aldrich (UK). Talc was ordered from Fluka Analytical (UK). Scotch blue painter's tape 50 mm was supplied by 3 M (Bracknell, UK). Eudragit L100-55 was donated by Evonik Industries (Darmstadt, Germany).
Preparation of Filaments Using HME
For the preparation of the core filaments, a Thermo Scientific HAAKE MiniCTW hot melt extruder (Karlsruhe, Germany) was utilised. An optimised ratio of a powder mixture constituting of the polymer (PVP), plasticizer (TEC), filler (talc) or tribasic phosphate sodium (TBP) and API (theophylline) respectively (Table I) was adapted from previous work (18) . The mixture was gradually added to the HME and allowed to mix for 5 min at 100°C to allow homogenous distribution of the molten mass. Afterwards, extrusion took place at 90°C at a torque of 0.4 Nm using a 1.25 mm nozzle size. Optimised filaments were also modified to include another two model drugs, budesonide (2.3%wt) and diclofenac sodium (20%wt). The change in drug concentration allowed achieving a representative dose for budesonide (3 mg) and diclofenac sodium (25 mg) from the model core. For the preparation of the shell, Eudragit L100-55, TEC and talc (50, 16.67 and 33.33%wt) were mixed at 135°C for 5 min in a HME and extruded at 125°C using 1 mm nozzle size.
Tablet Design and Printing
The core-shell tablets were designed in a caplet shape as described in a previous study (18) . In order to assess the impact of shell thickness, a number of designs with increasing shell thicknesses (0.17, 0.35, 0.52, 0.70 or 0.87 mm) were constructed. All the shell designs were complementary to the same core. Shell-core tablets were printed using modified settings of the software: Shell and core printing temperatures were 185 and 110°C respectively and the platform was heated to 40°C. The first layer, infill, inset and outline layers were printed at 12 mm/s extrusion speed and 50 mm/s travelling speed. The resolution was set as standard (200 μm layer thickness). In a separate experiment and in order to assess the impact of 3D printing resolution, the shell-core theophylline tablet design with 0.52 mm shell thickness were printed at low, standard and high resolutions.
Thermal Analysis
For modulated temperature differential scanning calorimetry (MTDSC) analysis, a differential scanning calorimeter (DSC) Q2000 (TA Instruments, Elstree, Hertfordshire, UK) was employed, using previously reported method in an earlier study (18) . In order to assess the impact of different lubricant on thermal stability of the PVP filament, TGA analysis was employed as previously specified (18) .
X-ray Powder Diffractometry (XRPD)
The physical form of model APIs in PVP, PVP: TEC filament, API-free and API-loaded filaments, and 3D printed tablets were assessed using a powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany). Samples were scanned from 2Theta (2θ) = 5°to 50°using previously reported parameters (18) .
Determination of Drug Content
In order to examine the effect of HME and FDM 3D printing on the integrity of API, API-loaded filaments and 3D printed tablets were analysed for drug content prior and following HME as well as in the 3D printed tablets. Samples (API loaded filaments or tablets) were accurately weighed and placed in a 500 mL of 0.1 N HCl, 1:1 water: acetonitrile mixture or phosphate buffer 6.8 for 2 h under sonication for theophylline, budesonide and diclofenac sodium respectively. The solutions were filtered through 0.22 μm Millex-GP syringe filters (Merck Millipore, USA) and prepared for HPLC analysis.
Theophylline content in relevant samples was assessed using an Agilent UV-HPLC 1260 series (Agilent Technologies, Inc., Germany) equipped with XTerra RP 18 column (150 × 4.6 mm, 5 μm particle size) (Waters, Ireland) at a temperature of 40°C. The mobile phase consists of a 10 mM solution of ammonium acetate buffer, methanol and acetonitrile (86:7:7). Analysis was carried out at a wavelength of 272 nm, flow rate of 1 mL/min, injection volume was 5 μL and a run time of 7 min.
Budesonide content was assessed using an Agilent UV-HPLC 1260 series (Agilent Technologies, Inc., Germany) equipped with synergy max column at 30°C. A mixture of acetonitrile and pH 3 water (55:45) was used as a mobile phase. Analysis was carried out at a wavelength of 244 nm, flow rate of 1.5 mL/min, injection volume was 50 μL and a run time of 10 min.
For diclofenac sodium, samples were assessed using an Agilent UV-HPLC 1200 series (Agilent Technologies, Inc., Germany) equipped with synergy fusion column at temperature 30°C. The mobile phase was made up of methanol and pH 2 water (80: 20). Analysis was carried out at a wavelength of 280 nm, flow rate of 1 mL/min, injection volume was 10 μL and a run time of 10 min.
Scanning Electron Microscopy (SEM)
Quanta-200 SEM microscope at 20 kV was used to examine the surface morphology of the printed shell-core structures. Samples were placed on a metallic stub and then gold coated under vacuum using JFC-1200 Fine Coater (Jeol, Tokyo, Japan). Images of the tablets were also taken using a Canon EOS-1D Mark IV (Canon Ltd, Japan).
Raman Spectroscopy
Raman spectroscopy (Horiba HR800, UK) was used to analyse and map the flat surface of the content of a 50% printed tablet. A green laser was used (532 nm) with 25% filter and 600 grating. The slit and hole were set to 100 and 300 μm respectively. An acquisition time of 2 s was used with an accumulation of 5 scans per point. Samples were scanned from 1200 to 1800 nm with a step size of 150 μm. The band for theophylline was assigned a red colour, whilst a green colour was assigned to Eudragit L100-55. Labspec 6 spectroscopy software suite (Horiba Scientific, Japan) was used to process the data.
In Vitro Disintegration and Dissolution Studies
Disintegration Tests
Disintegration studies were conducted following United States Pharmacopeia 30 standards (9). Six tablets were placed in the baskets of DT700 disintegration apparatus (Erweka, Germany) and were shaken for an hour in 0.1 M HCl. The gastric medium was then replaced with phosphate buffer pH 6.8. The experiment was continued and the time for complete disintegration of all tablets was recorded.
Acid Uptake Tests
In order to assess the ability of the 3D printed enteric shell to protect the core, three coated tablets were weighed individually prior to 2-h exposure to 0.1 M HCl at 37°C. The tablets were then drained off the acidic medium, dried with filter paper and weighed again. The acid uptake was calculated as follows:
Weight gain % ð Þ ¼ wet mass -dry mass dry mass Â 100
pH Change Dissolution Test (Phosphate Buffer)
In vitro drug release studies for all gastro-resistant tablets used in this study were conducted using an AT 7 Smart dissolution USP II apparatus (Sotax, Switzerland). Each experiment was carried out in triplicate in dissolution medium at 37 ± 0.5°C with a paddle speed of 50 rpm. The tablets were tested in 750 mL of a stimulated gastric fluid (0.1 M HCl, pH 1.2) for 2 h, followed by 4-h exposure to pH 6.8 phosphate buffer. Within all the experiment the amount of released theophylline was determined at 5 min intervals by UV/VIS spectrophotometer (PG Instruments Limited, UK) at a wavelength of 272 nm and path length of 1 mm. Data was analysed using IDISis software (Automated Lab, 2012). For budesonide and diclofenac sodium, samples (2 mL) were manually collected at 0, 15, 30, 60, 90, 120, 150, 165, 180, 210, 240, 300, 360, 420 and 480 min. They were then assessed using the HPLC methods outlined in the HPLC method described in BDetermination of Drug Content^section.
pH Change Dissolution Test (Bicarbonate Buffer)
In order to assess the drug release pattern in a more physiologically relevant medium, an additional evaluation of drug release was performed in pH 7.4 modified Krebs bicarbonate buffer. The latter better simulates the buffer capacity, pH and ionic composition of human gastric fluids (28) .
The dissolution test was carried out following the same protocol specified in the previous section (pH Change Dissolution Test (Phosphate Buffer)). For the first 2 h, tablets were exposed to 900 mL of 0.1 HCl (pH 1.2). Tablets were then retrieved from the acidic medium and introduced into 900 mL of modified Krebs buffer for an additional 4 h (1.18 mM KH 2 PO 4 , 24 mM NaHCO 3 , 118.07 mM NaCl, 4.69 mM KCl, 2.52 mM CaCl 2 , and 1.18 mM MgSO 4 · 7H 2 O).
Statistical Analysis
One-way ANOVA was employed using SPSS Software (22.0.0.2) to analyse the results. Differences in results of p < 0.05 were considered to be significant. Figure 1 provides a schematic illustration of the fabrication of 3D-printed shell-core enteric tablets. CAD software was utilized to design two complementary stereolithographic files to form a shell-core structure. Dual FDM 3D printer was employed with two different filaments; i) filament for enteric shell (Eudragit L100-55), and ii) filament for the core (API, PVP) processed through an HME compounder. Theophylline was used as a model drug to develop the enteric core structure due to its high solubility in acidic medium and small molecular weight, rendering it a major challenge for an enteric system (29) .
RESULTS AND DISCUSSION
Unlike single FDM 3D printing of theophylline (18), frequent blocking of PVP filament (core) was encountered in dual FDM 3D printing. It is possible that whilst the first nozzle is printing, the filament in the second nozzle remains at elevated temperature leading to material adherence to the inner wall of the nozzle head. To overcome the frequent blocking of the nozzle, several additives were initially incorporated in PVP filament composition. However, it led to the softening of the filament and rendered it incompatible with the gears of the 3D printer. An alternative solution was the addition of lubricant liquids with high boiling points (castor oil, oleic acid or PEG 400). All three liquids allowed successful printing of tablets without affecting the TGA patterns of the polymer (Supplementary Data, Fig. S1A ) or the dissolution rate of theophylline from the filaments (Supplementary Data, Fig. S1B ). It is likely that these liquids exhibit a lubricating rather than protective effect and physically prevents the sticking of the filament to the internal wall of the nozzle, hence allowing smooth alternations between nozzles. Based on these findings it was decided to choose one lubricant, oleic acid to facilitate dual 3D printing.
Following the optimisation of the core matrix, it was possible to graft a shell material based on developing a filament comprising of Eudragit L100-55, TEC and talc at a ratio of: 50, 16.67 and 33.33%wt, respectively. Eudragit L100-55 is a methacrylic acid-ethyl acrylate copolymer (1:1) commonly used for the preparation of enteric solid dosage forms. Its unique structure gives it a pH-dependent character, being insoluble at physiological pH values and soluble above pH 5.5 medium (30). The used ratio was deemed necessary to significantly lower the Tg of Eudragit L100-55 from 125.53 to 10.23°C (Supplementary Data, Fig. S2 ) to allow continuous flow from FDM 3D printer's nozzle, whilst solidifying quickly to permit the formation of a well-defined structure.
In order to adjust the pH response release pattern of coreshell structures, tablets with identical cores comprising theophylline as a model drug were fabricated with increasing thicknesses of the Eudragit L100-55 shell (Fig. 2a-d) . In vitro dissolution tests indicated that thickness levels 0.17 and 0.35 mm led to a premature release of the drug in the acidic medium (Fig. 2e) . It is possible that these thicknesses only allowed the printing of 1-2 layers in the shell structure, which was insufficient to control drug release. When a thicker shell design was applied (0.52, 0.7 or 0.87 mm), a superior control of drug release was achieved (<3% of drug released after 120 min in gastric medium). This was accompanied with the formation of larger number of layers (3-5 layers), which is essential to construct a gastric-resistant barrier to the acidic medium. It is notable the drug release in the intestinal phase (pH 6.8) followed a bi-phase pattern; a relatively slow drug release in the initial 45 min after pH change followed by a faster release after 45 min. It is possible that the first phase reflects the diffusion of the model drug through the eroding enteric shell layers, whilst a faster release takes place following the complete dissolution of the shell, where a water-soluble PVP-based core starts to dissolve. Such a pattern has been seen in shell-core structures (25) , where erosion of the external layer preceded the dissolution of the core.
The impact of FDM 3D printing resolution (layer thickness) on the dissolution of shell-core structures was also investigated using 0.52 mm shell (Fig. 3a) . Reducing the resolution of the 3D printing (reducing number of layers to fabricate the shell) in low and standard resolutions resulted in a relatively slower response to pH change in comparison to high resolution (Fig. 3b) . It is worthy to note that using FDM 3D printing, a much thicker shell layer was needed to achieve sufficient gastric resistant pattern in comparison to conventionally coated tablets with fluid-bed or pan coater (30-100 μm) (31) which reflects the difficulty of producing a complete protective layer with a single layer of filament. In order to accelerate drug release in the intestinal phase, an alkalinizing agent, tribasic phosphate sodium (TBP), was examined as a filler in a replacement for talc. The strategy allowed a much faster dissolution pattern in the intestinal phase (Fig. 3c) , it is likely that TBP in the core would dissolve with water imbibition upon pH change, leading to a rise in the local pH and resulting in acceleration of dissolution of Eudragit L100-55 shell and hence faster release of the API (32) . However, the use of TBP was associated with a drop in weight as revealed by TGA (Supplementary Data, Fig. S3 ). HPLC analysis confirmed a significant drop in drug content (86%) ( Table I ). These findings suggest that, unlike talc which acts as an inert filler, TBP tends to react with theophylline at an elevated temperature leading to a significant drug degradation. Hence, talc was considered as the filler of choice for this study.
Raman spectral mapping was utilised to generate a detailed chemical image of the flat surface of a 50% complete 3D printed tablet (Fig. 3D1) . Interrogation of individual spectra to produce false colour representations of distribution for theophylline (green) and Eudragit L100-55 (red) elucidated a definitive separation between the core and the shell (Fig. 3D2) , suggesting the presence of theophylline in the core of the tablet with no signs of it diffusing into the Eudragit L100-55 shell.
In order to prove the suitability of the system to different APIs, two other model drugs, budesonide or diclofenac sodium, were also examined by including them individually in the PVP based filament. TGA thermographs (Fig. 4a-b) showed a mass drop of PVP filaments around 100°C due to water loss whilst a second major mass drop was also apparent at 400°C due to the degradation of PVP. The thermal stability of both model APIs, similar to earlier studies, showed no further weight loss at temperatures <200°C for budesonide (20) and diclofenac sodium (33) .
Analogous to TGA results, DSC thermographs of PVP displayed a large endothermal event in the range of 50-110°C due to polymer dehydration as established in our previous study (18) . This was attributed to the hygroscopic nature of PVP (34) . Our previous investigation using modulated heatscan and heat-cool-heat scan indicated that water content plays a major role as a plasticizer for PVP filament (18) . The Tg of PVP filament (plasticised with TEC) were in much lower range (19-35°C) than expected from Gordon-Taylor equation (Tg =82.3°C). However, the Tg obtained in the second heat flow (following water evaporation) was 93°C.
The addition of budesonide appeared to have a limited effect on the Tg of the filament and the tablet (Fig. 5a ). This might be due to the limited concentration of budesonide in the product (2.3%). In case of diclofenac sodium, when same level of plasticization was initially investigated (12.5%), a brittle filament was produced with a higher Tg (44.89°C) (Supplementary Data, Fig. S4 ). In fact, a high level of plasticization (TEC 17.5%) was deemed necessary to produce a compatible filament, this was reflected with a shift of Tg upon the addition of diclofenac sodium to 16.27°C (Fig. 5b) . The addition of theophylline on the other hand as reported in our earlier work led to a depression in the Tg of the filament (18) . Such a shifts can be attributed to the plasticizing effect of theophylline (35) .
The XRPD patterns of budesonide loaded filament and tablets (Fig. 6 ) exposed the absence of peaks at (2θ) = 6.2, 12.1, 15.5, 16.1, 22.9°indicating no crystalline presence in the PVP matrices (36, 37) . For diclofenac sodium, XRPD spectra demonstrated several diffraction peaks at (2θ) =11.3, 15.3, 23.5° (38) . However, the absence of such peaks in the XRPD of the API loaded filament matrix and tablet suggests that the majority of diclofenac sodium remained in the amorphous form. On the other hand, as reported in our earlier study (18) theophylline remained in a crystalline form in the PVP-talc based matrix.
The dissolution pattern of all tested APIs indicated a pHdependant drug release (Fig. 7a) . When these tablets were assessed in more physiologically relevant dissolution medium (28), a slower dissolution pattern was noted (Fig. 7b) . Such effect might be related to the lower buffer capacity of bicarbonate buffers in comparison to phosphate based ones (39) .
The faster drug release of diclofenac sodium in comparison with budesonide might be related to its higher drug loading as well as solubility of (26 mg/mL) (40) in comparison to budesonide (0.0429 mg/mL) (41) .
The disintegration test indicated that all tablets remained intact after 1 h in the disintegration medium (Table II) . However, upon pH change the disintegration time was significantly longer than the Pharmacopeial standards (9) . Such behaviour is related to the nature of core, where polymeric matrices erodes slowly upon exposure to media rather than the exploding of the core in tablets produced by powder compression. The acid uptake behaviour indicated a relatively high acid uptake (Table II) . However, these results should be interpreted with caution when compared to coated tablets, Fig. 7 In vitro release pattern of APIs; budesonide, diclofenac sodium or theophylline from 3D printed tablets using a USP II pH change dissolution test in (a) phosphate buffer and (b) bicarbonate buffer. where weight gain of 3-7% of the enteric coating is usually applied to achieve protection. In the presented example, the shell represents approximately 50% of tablet's total weight. In summary, by adapting FDM 3D printing to two polymeric matrices and co-coordinating the construction of core and shell structures, the potential of 3D printing technology in fabricating patient-specific pH-responsive tablets has been demonstrated.
CONCLUSION
It was possible to fabricate tablets based on shell-core structure with increasing shell thicknesses using dual FDM 3D printing. Following pH change dissolution test, it was necessary to obtain a shell thickness ≥0.52 mm in order to achieve sufficient core protection in the acid medium. To the author's knowledge, this is the first report of producing delayed release tablets based on a 3D printing technology. The process presents a single step production method for gastric-resistant products. This work illustrates the potential of employing dual FDM 3D printing to overcome the rigidity of traditional techniques of manufacturing delayed release solid dosage forms in response to demands from clinical and industrial sectors.
